Literature DB >> 2788508

Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin.

P A Paciucci1, J F Holland, J S Ryder, R G Konefal, G J Bekesi, R Odchimar, R Gordon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2788508     DOI： 10.1016/0305-7372(89)90026-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

1.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.

Authors:  C Fortis; E Ferrero; M Biffi; S Heltai; C Besana; E Bucci; M Tresoldi; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

Authors:  D V Spicer; A Kelley; R Herman; G Dean; L Stevenson; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

5.  Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.

Authors:  J Hamuro; T Kikuchi; F Takatsuki; M Suzuki
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.